outpatient trials

Milestone nets $80M for at-home trial of tachycardia nasal spray

Milestone Pharmaceuticals has brought in $80 million to fund an at-home, phase 3 clinical trial of its nasal spray for bringing down high heart rates.

Conor Hale Oct 25, 2018 9:00am